natgillin/translations-raw huggingface dataset:
100 mg to gange dagligt end for placebo i intervallet på 6 måneder i studie 2 og numerisk højere end for placebo i studie 1.
100 mg twice daily over 6 month interval in Study 2 and numerically higher than placebo in Study 1.
100 mg to gange dagligt.
100 mg twice daily.
100 mg tre gange dagligt
100 mg three times a day
100 mg tyggetabletten har appelsin-banansmag og kan deles i to lige store dele om nødvendigt; det skal dog helst undgås at bryde tabletterne.
The 100 mg chewable tablet is orange-banana flavoured and can be split into equal halves if necessary; however, breaking the tablets should be avoided.
100 mg x 2
300 mg once daily
100 mg én gang daglig
100 mg once daily
100 mg én gang dagligt
100 mg once a day
100 mg én gang dagligt.
ritonavir 100 mg once daily.
100 mg/4 uger eller 150 mg/4 uger) med placebo, var alle tre doser af Xeplion bedre end placebo til at forbedre den samlede PANSS-score.
150 mg/4 weeks) to placebo, all three doses of Xeplion were superior to placebo in improving the PANSS total score.
100 mg/dag (én gang dagligt)
increments of 100 mg
100 mg/dag*
100 mg / day
100 mg/dag*
100 mg/day
100 mg/dag.
100 mg/d.
100 mg/m2 /dag, i fald det er nødvendigt), eller terapien kan afbrydes.
100 mg/m2/day) or treatment discontinuation.
100 mg/tenofovir 300 mg 1 gang
100 mg/tenofovir 300 mg once daily,
100 mg: 56 og 98 smeltetabletter
100 mg: 56 and 98 orodispersible tablets
100 mg: Røde uigennemsigtige/røde uigennemsigtige hårde gelatinekapsler, størrelse ”3”, præget med ‘‘PG’ på hætten og ‘100’ på kroppen.
Red opaque/ Red opaque, size “3” hard gelatin capsules imprinted with ‘PG’ on cap and ‘100’ on body.
100 mikrogram
100 micrograms
100 mikrogram
100 micrograms / dose
100 mikrogram
Preotact
100 mikrogram er lilla.
100 micrograms labelling is purple
100 mikrogram ETIKET TIL FYLDT INJEKTIONSSPRØJTE
100 micrograms PRE-FILLED SYRINGES LABEL
100 mikrogram fentanyl (som citrat)
100 micrograms fentanyl (as citrate)
100 mikrogram/
100 micrograms/ml
100 mikrogram/l eller med transferrinmætning under 20 %.
100 microgram/l or with transferrin saturation below 20%.
100 mikroliter opløsning i et hætteglas (type I-glas) med en prop (elastomergummi) og en 18 G filterkanyle (elastomergummi).
100 microlitres of solution in a vial (type I glass) with a stopper (elastomeric rubber), and an 18 G filter needle.
100 ml
100 ml (50 doses).
100 ml (1 doseringssprøjte)
100 ml (1 measuring syringe)
100 ml (100 doser)
100 ml (100 doses)
100 ml (50 doser)
100ml (50 doses)
100 ml (50 doser) hætteglas 250 ml (125 doser) hætteglas
100 ml (50 doses) 250 ml (125 doses)
100 ml 100 % appelsinjuice eller
100 ml 100 % orange juice
100 ml eller 250 ml flaske.
100 or 250 ml bottle with a measuring syringe.
100 ml flerlagspose af polyolefin/styren-ethylen-butylen (SEB) med SFC polypropyleninfusionsport lukket med gummiprop og låg.
100 ml multilayer polyolefin/styrene-ethylene-butylene (SEB) bag with SFC polypropylene infusion port closed with rubber stopper and snap cap.
100 ml glasflaske (med børnesikret propylenskruelåg, ydre del: polyethylen, indre del: polypropylen, foring: polyethylen)) med 30 g pulver til oral suspension, en plastikadaptor (lavdensitet polyethylen),, en plastik oral dispenser (30 mg, 45 mg og 60 mg inddelinger) (cylinder og stempel : polypropylen, siliconbaseret tætningsring) og et plastikmålebæger (polypropylen).
100 ml amber glass bottle (with child-resistant polypropylene screw cap, outer part: polyethylene; inner part: polypropylene; liner: polyethylene) with 30 g of powder for oral suspension, a plastic adapter (low density polyethylene), a plastic oral dispenser (30 mg, 45 mg and 60 mg graduation) (barrel and plunger: polypropylene; silicon based seal ring) and a plastic measuring cup (polypropylene).
100 ml hætteglas
100 ml
100 ml infusionsvæske i en farveløs plastikflaske (cykloolefinik-polymer) lukket med fluor-polymer- dækket bromobutyl-gummiprop og et aluminium/polypropylen-fliplåg.
100 ml solution in a transparent plastic (cycloolefinic polymer) bottle closed with a fluoro-polymer coated bromobutyl rubber stopper and an aluminium/polypropylene cap with a flip component.
100 ml og 250 ml HDPE-flasker
100 ml and 250 ml HDPE bottles
100 ml opløsning i en farveløs glasflaske af type I med en prop af halobutylgummi, der er overtrukket med fluorpolymer og et ”flip-off” låg af aluminium.
100 ml solution in colourless glass bottle type I with fluoropolymer coated halobutyl rubber stopper and aluminium flip-off cap.
100 ml PET hætteglas, klare
50 ml PET vials, clear 100 ml PET vials, clear
100 ml plastikflaske (cykloolefin coplymer), der er lukket med en brombutyl-gummiprop og forsynet med et aluminiumslåg med en blå flip-off plastskive.
100 ml Cyclic Olefin Polymer (COP) plastic bottle, fitted with a chlorobutyl/butyl rubber stopper and aluminium cap fitted with blue plastic flip off disc.
100 ml plastikflaske (cykloolefinik polymer) lukket med chlorbutylgummiprop og et aluminium fliplåg med violet flip-off plastskive.
100 ml Cyclic Olefin Polymer (COP) plastic bottle, fitted with a chlorobutyl/butyl rubber stopper and aluminium cap fitted with violet plastic flip off disc.
100 ml/time
100 mL/hour
100 overtrukne tabletter
100 coated tablets
100 patienter [behandlingsnaive (n = 29) eller tidligere behandlet med agalsidase beta, som skiftede til Replagal (n = 71)] blev behandlet i op til 30 måneder i et åbent, ikke-kontrolleret studie.
100 patients [(naïve (n=29); or previously treated with agalsidase beta who switched to Replagal (n=71)) were treated for up to 30 months in an open label, uncontrolled study.
100 patienter blev oprindeligt behandlet med Kaletra i studiet (inklusive 51 patienter, der fik 400/100 mg to gange daglig og 49 patienter på enten 200/100 mg to gange daglig eller 400/200 to gange daglig).
One hundred patients were originally treated with Kaletra in the study (including 51 patients receiving 400/100 mg twice daily and 49 patients at either 200/100 mg twice daily or 400/200 mg twice daily).
100 patienter blev oprindeligt behandlet med Kaletra i studiet (inklusive 51 patienter, der fik 400/100 mg to gange daglig, og 49 patienter på enten 200/100 mg to gange daglig eller 400/200 to gange daglig).
One hundred patients were originally treated with Kaletra in the study (including 51 patients receiving 400/100 mg twice daily and 49 patients at either 200/100 mg twice daily or 400/200 mg twice daily).
100 patienter deltog derefter i den anden del af undersøgelsen, hvor Ilaris blev sammenlignet med placebo.
One hundred patients then entered the second part of the study, which compared Ilaris with placebo.
100 patientår for patienter, der fik placebo.
100 patient-years for placebo-treated patients.
100 patientår for tocilizumab-behandling.
0.26 events per 100 patient years with tocilizumab therapy.
100 patientår i MTX-gruppen.
100 patient years of exposure in the MTX group.
100 patientår i opfølgningsperioden for patienter behandlet med ustekinumab (1 patient i 829 patientår i opfølgningsperioden) sammenlignet med 0,26 patienter behandlet med placebo (1 patient i 385 patientår i opfølgningsperioden).
100 patient-years of follow-up for ustekinumab-treated patients (1 patient in 829 patient-years of follow-up) compared with 0.26 for placebo-treated patients (1 patient in 385 patient-years of follow-up).
100 patientår i opfølgningsperioden for patienter i ustekinumab-armen (1 patient i 829 patientår i opfølgningsperioden) sammenlignet med 0,26 i placebo-armen (1 patient i 385 patientår i opfølgningsperioden).
100 patient-years of follow-up for ustekinumab-treated patients (1 patient in 829 patient-years of follow-up) compared with 0.26 for placebo-treated patients (1 patient in 385 patient-years of follow-up).
100 patientår) var 1,05 i insulin glargin 100 enheder/ml-armen og 0,30 i standardbehandlings-armen, og forekomsten af bekræftet ikke-alvorlig hypoglykæmi var 7,71 for insulin glargin 100 enheder/ml og 2,44 for standardbehand- ling.
1.05 for insulin glargine 100 units/ml and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine 100 units/ml and 2.44 for standard care group.
100 patientår) var 1,05 i insulin glargin- armen og 0,30 i standardbehandlings-armen, og forekomsten af bekræftet ikke-alvorlig hypoglykæmi var 7,71 for insulin glargin og 2,44 for standardbehandling.
1.05 for insulin glargine and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard care group.
100 patientår.
0.6 events per 100 PYs.
100 patientår.
100 patient years of use.
100 patientårs eksponering viste, at kun forekomsten af diarré var signifikant højere hos børn (11,05) end hos voksne (2,01, p=0,01).
100 patient-years of exposure showed that only the rate of diarrhoea was significantly higher in children (11.05) than in adults (2.01, p=0.01).
100 pipetter
100 pipettes
100 poser
100 sachets
100 resoribletter
100 tablets
100 smeltetabletter
100 orodispersible tablets
100 tabletten
100 tablets
100 tabletter
100 x 1 tablets
100 tabletter
20 tablets
100 tabletter
6 tablets
100 tabletter
EU/1/12/755/018 [100 tablets]
100 tabletter
EU/1/12/755/027 [100 tablets]
100 tabletter
EU/1/12/756/018 [100 tablets]
100 tabletter
tablet
100 tabletter i HDPE-flaske:
100 tablets HDPE bottle:
100 tabletter: EU/1/08/469/005
100 tablets: EU/1/08/469/005
100 tabletter: EU/1/08/469/010
100 tablets: EU/1/08/469/010
100 tabletter: EU/1/08/469/015
100 tablets: EU/1/08/469/015
100 tabletter: EU/1/08/469/020
100 tablets: EU/1/08/469/020
100 tabletter: EU/1/08/469/025
100 tablets: EU/1/08/469/025
100 tabletter: EU/1/10/632/022
100 tablets: EU/1/10/632/022
100 tabletter: EU/1/10/632/023
100 tablets: EU/1/10/632/023
100 tabletter: EU/1/10/632/024
100 tablets: EU/1/10/632/024
100 Tasigna 300 mg 2 gange dagligt (n = 282)
100 Tasigna 300 mg twice daily (n = 282)
100 x 1 (enhedsdosis)
100 x 1 (Unit dose)
100 x 1 (enhedsdosis))
100 x 1 (Unit dose)
100 x 1 (enkeltdosis)
100 x 1 (unit dose)
100 x 1 eller i multipakker med 10 æsker med 10 x 1 filmovertrukne tabletter.
30 film-coated tablets or unit dose blisters in cartons of 10 x 1 or 100 x 1 or in multipacks comprising 10 cartons, each containing 10 x 1 film-coated tablets.
100 x 1 filmovertrukken tablet
100 x 1 film-coated tablet
100 x 1 filmovertrukne tabletter
100 X 1 film-coated tablet
100 x 1 filmovertrukne tabletter
100 x 1 film-coated tablets
100 x 1 filmovertrukne tabletter.
100 x 1 film-coated tablets
100 x 1 hårde enterokapsler
100 x 1 hard gastro-resistant capsules
100 x 1 hårde kapsler
100 x 1 hard capsules
100 x 1 kapsler
100 x 1 capsules
100 x 1 kapsler
100 x 1 capsules (unit
100 x 1 kapsler (enkeltdosis)
100 x 1 capsules (unit dose)
100 x 1 kapsler (enkeltdosis) 100 kapsler
100 x 1 capsules (unit dose)
100 x 1 tablet
100 x 1
100 x 1 tablet
100 x 1 tablets (unit dose)
100 x 1 tablet (enhedsdosis)
100 x 1 tablet (unit dose)
100 x 1 tablet (enkeltdosis)
100 x 1 tablet (unit
100 x 1 tabletter
100 x 1 tablets (unit
100 x 1 tabletter (enhedsdosis)
100 x 1 tablets (unit dose)
100 x 1 tabletter (enhedsdosis)
100 x 1tablets (unit dose)
100 x 1 tabletter (enhedsdosis)
100x1 tablets (unit dose)
100 µg
15 µg
100 µg
150 µg
100 µg
40 µg
100 µg
500 µg
100 µl pumpe
100µl pump
100 µl pumpe
and 100 µl pump
100 × 1 filmovertrukne tabletter
100 x 1 film-coated tablets
100% (1 IE/ml)
100 % (1 IU/mL)
100% (3/3)
without Q80K
100% sevofluran
100% sevoflurane
100%. tmax er mellem 3 og 8 timer.
Tmax is between 3 and 8 hours.
100%. tmax er mellem 3 og 8 timer.
Tmax is between 3 and8 hours.
100, 2 x 100 og 200 ml flaske
100 ml, 2 x 100 ml and 200 ml bottle
100, 200 og 250 ml
100, 200 and 250 ml
100-101 Terrasse Boieldieu Tour Franklin- La Défense 8 92042 Paris la Défense Cedex FRANKRIG
100-101 Terrasse Boieldieu Tour Franklin- La Défense 8 92042 Paris la Défense Cedex FRANCE
100-119,9 kg
100 to 119.9 kg
100-150 mg 2 gange daglig
100-150 mg BID
100-180 mg
100 – 180 mg
100-200 mg 3 gange
100-200 mg TID
100-200 mg 3 gange daglig
100-200 mg TID
100-200 mg 3 gange dagligt
100-200 mg TID
100.000 kopier/ml
< 100,000 copies/ml
100.000 kopier/ml
 100,000 copies/ml
100/25 mg tablet to gange dagligt baseret på vægt uden nevirapin er undersøgt hos i alt 53 pædiatriske patienter.
Kaletra 100/25 mg tablet twice-daily weight-band dosing without nevirapine have been studied in a total of 53 paediatric patients.
100/25 mg tabletter- beholderetiket
100 mg/25 mg tablets - bottle label
100/25 mg tabletter- æske med 1 beholder
100 mg/ 25 mg tablets – Carton of 1 bottle
1000
1000 IU
1000 (20 x 50) tabletter
1000 tablets (20 x 50 tablets)
1000 Bruxelles Belgien medinfoeuceemea@shire.com
1000 Brussels Belgium medinfoeuceemea@shire.com
1000 enheder Cinryze inden for 24 timer før et medicinsk, dentalt eller kirurgisk indgreb.
1000 Units of Cinryze within 24 hours before a medical, dental, or surgical procedure.
1000 enheder Cinryze ved det første tegn på fremkomst af et angioødem-anfald.
1000 Units of Cinryze at the first sign of the onset of an angioedema attack.
1000 IE (100 IE/ml efter rekonstituering)
1000 IU (100 IU/ml after reconstitution)
1000 IE /
1000 IU /
1000 IE moroctocog alfa til engangs IV brug
1000 IU moroctocog alfa for single IV use
1000 IE octocog alfa
1000 IU octocog alfa
1000 IE octocog alfa (400 IE/ml efter opløsning).
1000 IU octocog alfa (400 IU/ml after reconstitution).
1000 IE* human koagulationsfaktor VIII** (FVIII)
1000 IU* human coagulation factor VIII** (FVIII)
1000 IE/hætteglas
1000 IU/vial
1000 IE: et glas (glastype I) med pulver + et glas (glastype I) med 10 ml solvens med propper (bromobutyl).
1000 IU: one vial (glass type I) of powder + one vial (glass type I) of 10 ml solvent with stoppers (bromobutyl).
1000 internationale enheder/hætteglas simoctocog alfa (400 IE/ml efter rekonstitution)
1000 International Units/vial simoctocog alfa (400 IU/ml after reconstitution)
1000 IU/ml efter rekonstitution)
1000 IU/mL after reconstitution)
1000 kvinder pr. år for raloxifen.
1000 women per year for raloxifene.
1000 mg breve
1000 mg sachets
1000 mg daglig ved kombination med capecitabin eller 1250 mg daglig ved kombination med en aromatasehæmmer).
1250 mg/day when administered with an aromatase inhibitor).
1000 mg pulver i et hætteglas af glas (type I), lukket med en gummiprop (brombutyl) og aluminiumsforsegling med en flip-off hætte af plastik.
1,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl) stopper and an aluminium seal with a plastic flip off cap.
1000 mg to gange daglig
1000 mg BID
1000 mg/kg/dag, og NOAEL for udviklingstoksicitet var <25 mg/kg/dag (AUC24h var 34.340 ng•t/ml på gestationsdag 17 ved denne lavest testede dosis, og eksponeringsratio var 85 gange i forhold til en klinisk dosis på 4 mg).
1000 mg/kg/day, and the NOAEL for developmental toxicity was <25 mg/kg/day (AUC24h was 34340 ng•h/mL on Gestation Day 17 at this lowest dose tested, and the exposure ratio was 85-fold relative to a 4 mg clinical dose).
1000 mg/m2 oral to gange dagligt
1000 mg/m2 oral twice daily
1000 mg:
For 1000mg:
1000 mg: 10, 20, 30, 50, 60, 100 og multipakning med 200 (2 pakninger af 100) filmovertrukne tabletter.
1000 mg: 10, 20, 30, 50, 60, 100 and multipack of 200 (2 packs of 100) film-coated tablets.
1000 mikrogram/10 ml
1000 micrograms/10 ml
1000 ml flaske
1000 ml bottle
1000 patientår i placebogruppen.
1,000 patient-years in the placebo group.
1000 svin med en gennemsnitlig legemsvægt på 50 kg).
1000 pigs with an average body weight of 50 kg).
1000 tabletter (20 x 50 tabletter)
1000 tablets (20 x 50 tablets)
1000-under 1500
1000 – Less than 1500
10000 enheder (U) tenecteplase per hætteglas
10,000 U tenecteplase per vial
10000 IE
10000 IU/1.0 ml
10000 IE /
10000 IU/1.0 m
10000 IE /
10000 IU/1.0 ml
10057 patienter, der blev behandlet for UA eller NSTEMI AKS
10,057 patients undergoing treatment of UA or NSTEMI ACS
100x1 filmovertrukne tabletter
100x1 film-coated tablets
100x1 filmovertrukne tabletter
90x1 film-coated tablets
100x1 tabletter (enhedsdosis)
EU/1/15/1073/020
100×1 kapsel
100×1 capsule
101 rue Saint Lazare 75009 PARÍS
101 rue Saint Lazare 75009 Paris
1010
Overall
1010 Wien Østrig
1010 Wien Austria
1010 Wien Østrig
Gonzagagasse 16/16 1010 Vienna Austria
102 tabletter
102 tablets
102 tabletter (17 blisterkort med 6 tabletter i hver)
102 tablets (17 blister strips with 6 tablets each)
102 tabletter (17 blisterkort med 6 tabletter i hver) Profender 150 mg/30 mg tabletter til store hunde:
102 tablets (17 blister strips with 6 tablets each) Profender 150 mg/30 mg tablets for large dogs
102 µg FeLV antigen
102 µg FeLV
102.
Week 102.
102. uge var 80 patienter stadig på infliximab-behandling og blandt disse var 71 (89 %) ASAS 20 respondere.
At 102 weeks there were 80 subjects still on infliximab treatment and among those, 71 (89%) were ASAS 20 responders.
102.7 mg saccharose
102.7 mg sucrose.
103 børn fik månedlige injektioner af palivizumab for første gang, og 119 børn fik behandling med palivizumab i 2 på hinanden følgende sæsoner.
One hundred and three (103) children received monthly palivizumab injections for the first time, and 119 children received palivizumab for two consecutive seasons.
103.7 -104.5 CCID50*
104.5 CCID50
1030, Wien, Østrig.
1030, Vienna, Austria.
104 (20 %) ud af de 511 patienter fik infektioner ≥ grad 3.
One hundred and four (20%) of the 511 patients experienced ≥Grade 3 infections.
104 (20 %) ud af de 511 patienter fik infektioner ≥ grad 3.
One-hundred and four (20%) of the 511 patients experienced ≥Grade 3 infections.
104 og 106)
co-infection
104 uger
52 weeks
1043 BW Amsterdam Nederlandene
1043 BW Amsterdam The Netherlands
105 (81 %) og 78 (61 %) patienter i henholdsvis VcTDx- og TDx-gruppen fik en enkelt autolog stamcelletransplantation.
One single autologous stem cell transplant was received by 105 (81%) patients and 78 (61%) patients in the VcTDx and TDx groups, respectively.
105 (81%) og 78 (61%) patienter i henholdsvis BTDx- og TDx-gruppen fik en enkelt autolog stamcelle- transplantation.
One single autologous stem cell transplant was received by 105 (81%) patients and 78 (61%) patients in the BTDx and TDx groups, respectively.
105 21 Stockholm, Sverige
105 21 Stockholm, Sweden
105 mg (1,05 ml) to gange dagligt
105 mg (1.05 ml) twice daily
105 tabletter
105 tablets
105,1 TCID50*
105.1 TCID50
1050 Brussels Belgien
1050 Brussels Belgium
1058 København K Danmark
1058 Kopenhagen K Denmark
106 (1 million) PFU/ml – kun til initialdosis.
106 (1 million) PFU/mL - For initial dose only.
106 patienter fik mindst en 50 mg dosis af sunitinib efter doseringsskema 4/2.
One hundred and six patients received at least one 50 mg dose of sunitinib on schedule 4/2.
106,3 - 108,3 CFU af levende Bordetella bronchiseptica bakterie stamme B-C2.
106.,3- 108.3 CFU of live Bordetella bronchiseptica bacteria strain B-C2.
106,3 - 108,3 CFU/dosis af B. bronchiseptica
106.3- 108.3 CFU/dose B. bronchiseptica
106,3 - 108,3 koloni dannende enheder (CFU) af levende Bordetella bronchiseptica bakterie stamme B-C2
106.3-108.3 colony forming units (CFU) of live Bordetella bronchiseptica bacteria strain B-C2
106,3 - 108,3 koloni dannende enheder (CFU) af levende Bordetella bronchiseptica bakterie stamme B-C2
106.3-108.3 colony forming units (CFU) of live Bordetella bronchiseptica strain B-C2
106,6 TCID50
106.6 TCID50
106b
212d
106b [86-128]
106b [86, 128]
107
N 242
108 (100 millioner) PFU/ml
108 (100 million) PFU/mL
108 (100 millioner) PFU/ml – til alle efterfølgende doser.
108 (100 million) PFU/mL - For all subsequent doses.
108 mg enfuvirtid
108 mg enfuvirtide
1081 HV Amsterdam Holland
1081 HV Amsterdam The Netherlands
109 x 106 celler/l
109 x 106 cells/l
109/l, grad 4 < 25 × 109/l); anæmi (hæmoglobin grad 3 ≥ 65–< 80 g/l, grad 4 < 65 g/l).
< 50 × 109/l, Grade 4 < 25 × 109/l); anaemia (haemoglobin Grade 3 ≥ 65 – < 80 g/l, Grade 4 < 65 g/l).
1093 patienter fik behandling med Plegridy i mindst 1 år, og 415 patienter fik behandling med Plegridy i mindst 2 år.
1093 patients received at least 1 year, and 415 patients have received at least 2 years of treatment with Plegridy.
1097 JB Amsterdam Holland
1097 JB Amsterdam The Netherlands
10doser – 20 ml hætteglas
20 ml vial
10Hepatitis kan udvikle sig til leversvigt.
10 Hepatitis may progress to liver failure.
10x 1 ml (1 dosis) 50x 1 ml (1 dosis) 1x 10 ml (10 doser)
10x 1 ml (1 dose) 50x 1 ml (1 dose) 1x 10 ml (10 doses)
10x 1.000 doser
10x 1,000 doses
10x 10.000 doser
10x 10,000 doses
10x 2.500 doser
10x 2,500 doses
10x 5.000 doser
10x 5,000 doses
10x 500 doser
10x 500 doses
10x1
10x1 tablets
10x1 filmovertrukne tabletter.
10x1 film-coated tablets.
10x1 kapsler + 1 inhalator.
10x1 capsules + 1 inhaler.
11 % og væskeretention (perifert ødem) 26 % vs.
11% and fluid retention (peripheral oedema) 26% vs.
11 %, p< 0,0001).
11 %, p < 0.0001).
11 (21%) patienter en stigning i baseline QTcF på ≥30 til<60 ms og en patient (2%) havde en stigning i baseline QTcF på ≥60 ms.
11 (21%) patients had an increase from Baseline in QTcF value ≥30 to <60 msec and 1 (2%) patient had an increase from Baseline in QTcF value of ≥60 msec.
11 EFT.
11 OJ No.
11 IE
11 IU
11 liter).
11 litres).
11 MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE)
11 MARKETING AUTHORISATION NUMBER
11 ml/20ml hætteglas
11 ml/20 ml vial
11 patienter indgik, og 9 patienter er stadig i studiet.
11 patients were enrolled and 9 patients are on-going in the study.
11 til 24 M
11 to 24 M
11 til 24 mdr
11 to 24 M
11 til under 14†
11 to less than 14
11 til under 25 kg
11 to less than 25 kg
11 uger, p = 0,0004) og forlængede overlevelsen (11 måneder vs.
11 weeks, p = 0.0004) and prolonged OS (11 months vs.
11 x 0,5 mg +
0.5 mg
11 x 0,5 mg + 14 x
11 x 0.5 mg + 14 x
11 – Mens den monterede injektionssprøjte stadig er fastgjort, roterer du hætteglasset forsigtigt for at opløse Betaferon- pulveret fuldstændigt.
11 - With the syringe assembly still attached, swirl the vial around gently to completely dissolve the dry Betaferon powder.
11% (4-19%)
11% (4 to 19%)
11%, p< 0,0001).
11%, p< 0.0001).
11%, p<0,0001).
11 %, p < 0.0001).
11%, p<0,0001).
11%, p<0.0001).
11%, p<0,0001).
11%, p0.0001).
11%, p<0,0001).
11%,p<0.0001).
11%, p<0,0001).-
11 %, p < 0.0001).
11%; p < 0,0001
11%; P < .0001
11, i forordning (EF) nr.
Tel: +44 (0) 1923 437672
11,1 (8,5 til 13,8)
5.4 (4.53 to 5.68)
11,1 (8,9;
N=64 43.8 (31.3,55.6)
11,2 %), drømmeforstyrrelser (11,3 % vs.
11.2%), abnormal dreams (11.3% vs.
11,2 %, p<0,001 for en forøgelse på ≥ 2 linjer og 9,7 % vs.
11.2%, p<0.001 for a gain ≥ 2 lines and 9.7% vs.
11,2%); Smerter
Asthenia (severe: 11.2%); Pain
11,25 (9,05-13,99)
Terfenadine
11,3 mg/tablet
11.3 mg/tablet
11,5 %
NA
11,5% (63/550)c
11.5% (63/550)c
11,6 (2,35)
Diff. of LS Means (SE)
11,6% af patienterne havde marginal zone lymfom og 7,1% havde småcellet lymfocytært lymfom.
11.6% of the patients had marginal zone lymphoma (MZL) and 7.1% had small lymphocytic lymphoma (SLL).
11,7 % ; 3,7 %
baseline period
11,7 % ; 3,7 %
Generalized Tonic-Clonic
11,7 (9,96 til 13,77)
11.7 (9.96 to 13.77)
11,8 % for telmisartan- og ramiprilbehandlede patienter.
11.8 % among telmisartan and ramipril treated patients, respectively.
11,8 til 13,6
11.8 to 13.6
11,84 (-3,4; 27,0)e
11.84 (-3.4, 27.0)e
11,9
Study 074
11,95
Increase in
11- Eventuelle luftbobler vil stige op i toppen af opløsningen.
11 - Any excessive air rises to the top of the solution.
11-, 16-, 18-relateret VaIN 2/3 var den 85,7 % (95 % CI: 37,6; 98,4) og imod HPV 6-, 11-, 16-, 18- relaterede kondylomer 80,3 % (95 % CI: 73,9; 85,3) i de kombinerede protokoller ved studieafslutning.
6-, 11-, 16-, 18-related VaIN 2/3 was 85.7% (95% CI: 37.6, 98.4), and against HPV 6-, 11-, 16-, 18- related genital warts was 80.3% (95% CI: 73.9, 85.3) in the combined protocols at end of study.
11-13 Moores Rd, Glenorie, NSW, 2157 Australien
11-13 Moores Rd, Glenorie, NSW, 2157 Australia
11.
SN: